"Designing Growth Strategies is in our DNA"
The Middle East & Africa is expected to witness growth in the global multiple sclerosis drugs market. It is projected to grow at a CAGR of 5.7% during the forecast period. The global market for multiple sclerosis drugs is projected to grow from USD 22.32 billion in 2022 to USD 31.90 billion by 2030.
Multiple sclerosis is caused when the immune system damages the nerves' protective membrane, disrupting the body’s normal functioning. The increasing prevalence of the disease has been fueling the demand for multiple sclerosis drugs. Moreover, the improving public healthcare system along with the rising awareness regarding multiple sclerosis treatment in countries of the region is estimated to aid the growth of the Middle East& Africa. market
Our report on the Middle East & African market covers the following countries/regions – GCC, South Africa, and the rest of Middle East & Africa.
Increasing Use of Monoclonal Antibodies for the Disease Treatment to Fuel Market Growth
Incorporation of monoclonal antibodies for the treatment of the disease has been increased recently. This is due to increasing awareness about the efficiency of monoclonal antibodies in multiple sclerosis disease treatment. Sales of molecular antibody drugs, such as Lemtrada and Ocrevus, have been increasing significantly.
Therefore, the increasing penetration of molecular antibody multiple sclerosis drugs has been fueling the Middle East & Africa multiple sclerosis drugs market growth.
Market Players’ Increasing Focus on Commercialization of MS Drugs in the Region to Fuel Market Growth
Market players have increased their focus on the commercialization of multiple sclerosis drugs in the region to increase the accessibility of effective treatment to patients.
The commercialization of these drugs has been fueling the market growth in the region.
High Cost Associated with the Disease Treatment through Drugs to Limit the Market Growth
Prevalence of the disease has been increasing significantly, which has been elevating the demand for effective treatment. However, high cost associated with the overall treatment through for multiple sclerosis drugs tends to limit the market growth.
Furthermore, due to the limitations associated with diagnosis of the disease, many times the patients are not aware about their disease. Due to this, they do not get accurate treatment. Such factors tend to limit the market growth.
Based on the Middle East & Africa multiple sclerosis drugs market share, Biogen, Novartis AG, and F. Hoffman-La Roche Ltd. are significant players operating in the market. The growth of these players is due to the strong product portfolio of these companies.
Other players, such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Bristol-Myers Squibb Company, have increased their focus on mergers and acquisitions to strengthen their position in the market.
To gain extensive insights into the market, Request for Customization
The research report provides qualitative and quantitative insights on the market and a detailed analysis of the market size & growth rate for all possible segments in the market. Along with the market forecast, the research report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights presented in the report are overview of the prevalence of the disease, pipeline analysis, new product launches, and key industry developments – mergers, acquisitions & partnerships, and the impact of COVID-19 pandemic on the market.
ATTRIBUTE | DETAILS |
Study Period | 2019-2030 |
Base Year | 2022 |
Estimated Year | 2023 |
Forecast Period | 2023-2030 |
Historical Period | 2019-2021 |
Growth Rate | CAGR of 5.7% from 2023 to 2030 |
Unit | Value (USD Billion) |
Segmentation | Drug Class; Route of Administration; Distribution Channel; and Country/Sub-Region |
By Drug Class |
|
By Route of Administration |
|
By Distribution Channel |
|
By Country/ Sub-Region |
|
Growing at a CAGR of 5.7%, the market will exhibit steady growth in the forecast period (2023-2030).
Increasing prevalence of multiple sclerosis and emphasis of market players on the launch of drugs in the region are fueling the market growth.
Biogen, Novartis AG, F. Hoffman-La Roche Ltd., and Sanofi are the major market players in the Middle East & Africa market.
South Africa dominated the market in 2022.
US +1 833 909 2966 ( Toll Free )